Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY:MRK)

82.76 +0.05 (+0.06%)
Official Closing Price Updated: 7:00 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
Dividend Investor Earning $5,200 A Month Shares His Top 7 Stock Picks – 'Getting Dividend is the Biggest Joy in My Life'
 
Via Benzinga
3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever
A good stock is an even better buy when it's on sale. 
Via The Motley Fool
Topics Intellectual Property Stocks
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks
If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive. 
Via The Motley Fool
Topics Retirement
MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period
Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was... 
Via StockStory
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy. 
Via Benzinga
3 Reasons We’re Fans of Merck (MRK)
Over the past six months, Merck’s stock price fell to $80.05. Shareholders have lost 6.6% of their capital, which is disappointing considering the S&P 500 has climbed by 5.4%. This may have investors... 
Via StockStory
Topics Stocks Supply Chain
IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x
The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed. 
Via Stocktwits
IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year
IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most subgroups. 
Via Benzinga
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today. 
Via The Motley Fool
Topics Intellectual Property
3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August
One reliable high-yielder, one dividend growth stock, and one turnaround story for dividend lovers in August. 
Via The Motley Fool
Topics Economy Intellectual Property
2 Cash-Producing Stocks for Long-Term Investors and 1 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Political Tremors Rattle Markets: The Profound Impact of U.S. Elections and Tariff Shocks
The intricate dance between political shifts and financial markets has once again taken center stage, demonstrating the profound influence of electoral outcomes and subsequent policy decisions on... 
Via MarketMinute
Topics Economy Government Stocks
Is It Time to Buy Biotech Stocks?
A surge in private market investment has investors wondering: Is it time to bet bigger on biotech? 
Via The Motley Fool
MERCK & CO. INC. (NYSE:MRK): A Top Dividend Stock with Strong Profitability and Financial Stability
Merck & Co. (MRK) is a top dividend stock with a 4.06% yield, strong profitability, and solid financials, making it a reliable choice for income investors. 
Via Chartmill
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Their steep payouts make them worth a look, but a big dividend doesn't inherently make a stock worth owning. 
Via The Motley Fool
Topics Stocks World Trade
Merck (MRK) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now. 
Via The Motley Fool
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
3 High-Yielding Dividend Stocks That Are Trading Near Their 52-Week Lows
If you are looking for dividend stocks, a good place to start is with unloved stocks like these, with yields of up to 6.4%. 
Via The Motley Fool
Topics Intellectual Property
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today
These stocks have all surged more than 1,000% since August 2020. 
Via The Motley Fool
Topics Artificial Intelligence
Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns
Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove investor interest. 
Via Benzinga
Topics Earnings
Why Merck Stock Slipped Today
A change in full-year guidance by management wasn't particularly welcome. 
Via The Motley Fool
Is Merck & Co Gaining or Losing Market Support?
 
Via Benzinga
Why Merck (MRK) Shares Are Sliding Today
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.2% in the afternoon session after the company reported second-quarter financial results that missed revenue expectations and revealed a... 
Via StockStory
Topics Artificial Intelligence Workforce
Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges
Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised. 
Via Benzinga
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events. 
Via Benzinga
These S&P500 stocks are gapping in today's session
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Tuesday and stay ahead of the market trends. 
Via Chartmill
Merck’s Full Year Guidance Disappoints Investors But Retail Pins Hopes On $3B Cost-Cutting Plan
The $3 billion will be reinvested to support new product launches and its pipeline across multiple therapeutic areas, Merck said. 
Via Stocktwits
Topics World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.